AccurEdit Therapeutics closed a $75 million Series A to develop its CRISPR-based medicine portfolio from Suzhou, one of the largest early rounds for a Chinese gene‑editing startup. The financing will accelerate preclinical programs, expand discovery capabilities and support IND-enabling studies for at least one lead candidate. Investors signaled continued appetite for gene‑editing platforms despite regulatory and manufacturing complexity. AccurEdit said proceeds will fund platform maturation and partnerships to move assets toward the clinic.